Thank you to our Foundational and Sustaining members
GREEN BAY, Wis. (WBAY) – Early detection is key when it comes to any type of cancer, but for many, there isn’t a test to help with early detection, like pancreatic cancer. Now there might be some hope. Grail, a health company, just announced the creation of a multi-cancer early detection blood test that can […]
Wesley Wierson is a passionate scientist and entrepreneur applying his expertise in gene-editing technology to solve consumer-level problems in society. He studied microbiology as an undergraduate, where he was first exposed to gene-editing technology through undergraduate research. As a Ph.D. student, he developed gene-editing technology that permits the integration of exogenous genes into the genome, thus […]
Contact: Michael Kujak, CEO612-910-9790 Shelli Lissick, Bellmont Partners651-276-6922 FOR IMMEDIATE RELEASE Francis Medical Adds Urology Company Coloplast to Roster of Investors The $4 million equity investment will support the company in optimizing its product design and executing a pivotal U.S. study MINNEAPOLIS (Sept. 29, 2020) – Francis Medical, Inc., an early stage company pioneering urological cancer treatments, […]
MINNEAPOLIS (June 9, 2020) – Francis Medical, Inc., a Minneapolis-based, privately held medical device company developing an innovative and proprietary water vapor ablation therapy for the treatment of prostate, kidney, and bladder cancer, announced the enrollment of their first patient in the company’s VAPOR 1 clinical study. VAPOR 1 is an early feasibility study evaluating the safety […]
ROCHESTER, Minn., December 11, 2019 – Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced the appointment of experienced life sciences investors Edwin M. Kania, Jr. and Nathan L. Stacy to the Company’s board of directors. Mr. Kania was named Chairman of the Board. Mr. […]
Phase 2 trial will evaluate combination of PD-1 inhibitor Libtayo® (cemiplimab-rwlc) and oncolytic virus Voyager-V1; preclinical research collaboration will explore new oncolytic virus treatments Vyriad to receive upfront payment and equity investment from Regeneron TARRYTOWN, N.Y., and ROCHESTER, Minn. (November 6, 2019) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Vyriad, Inc. today announced a research collaboration and option […]
MINNEAPOLIS, July 17, 2019 /PRNewswire/ ‐‐ Bio‐Techne Corporation (NASDAQ: TECH) today announced the launch of a new 8‐Plex cartridge format for the ProteinSimple™‐branded Ella™ automated immunoassay platform. This new cartridge format analyzes 32 samples for eight distinct analytes, bringing higher multiplex capabilities to the Ella platform. The 32×8 cartridge for Ella enables users to build […]
On March 21st, Boston Scientific announced its intent to acquire Medical Alley-based NxThera, a medical device company developing the Rezūm system, a revolutionary, safe, and cost-effective minimally invasive treatment option for men suffering from benign prostatic hyperplasia (BPH). “We are excited to announce this agreement with Boston Scientific,” said Bob Paulson, president and chief executive […]